# Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis

> **NCT04676555** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2 (actual)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab
- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT04676555
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2021-10-21
- **Final completion:** 2021-10-21
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2022-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676555, "Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04676555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*